Enrico Smeraldi

Enrico Smeraldi's AcademicInfluence.com Rankings

Enrico Smeraldi

Biology

#8903

World Rank

#12041

Historical Rank

Genetics

#898

World Rank

#994

Historical Rank

Neuroscience

#1271

World Rank

#1316

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Enrico Smeraldi Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Enrico Smeraldi's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. (1996) (710)
Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine (1998) (599)
Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. (2000) (314)
Morning sunlight reduces length of hospitalization in bipolar depression. (2001) (311)
Influence of CLOCK gene polymorphism on circadian mood fluctuation and illness recurrence in bipolar depression (2003) (311)
[18F]FDG PET Study in Obsessive–Compulsive Disorder (1995) (286)
Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. (2010) (263)
Genetic dissection of psychopathological symptoms: Insomnia in mood disorders and CLOCK gene polymorphism (2003) (250)
Rate of switch from depression into mania after therapeutic sleep deprivation in bipolar depression (1999) (248)
Increased right caudate nucleus size in obsessive-compulsive disorder: Detection with magnetic resonance imaging (1992) (230)
Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-httlpr in delusional and nondelusional depression (2001) (210)
Disruption of White Matter Integrity in Bipolar Depression as a Possible Structural Marker of Illness (2011) (199)
Actimetric evidence that CLOCK 3111 T/C SNP influences sleep and activity patterns in patients affected by bipolar depression (2007) (192)
A glycogen synthase kinase 3-β promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression (2004) (190)
Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-β −50 T/C SNP (2005) (177)
Psychiatric disorders in the families of patients with obsessive-compulsive disorder (1992) (175)
A single nucleotide polymorphism in glycogen synthase kinase 3-β promoter gene influences onset of illness in patients affected by bipolar disorder (2004) (170)
Combined total sleep deprivation and light therapy in the treatment of drug-resistant bipolar depression: acute response and long-term remission rates. (2005) (164)
Influence of a functional polymorphism within the promoter of the serotonin transporter gene on the effects of total sleep deprivation in bipolar depression. (1999) (163)
Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity (2001) (163)
How long should pindolol be associated with paroxetine to improve the antidepressant response? (1997) (161)
Insomnia improvement during antidepressant treatment and CLOCK gene polymorphism (2005) (160)
Functional and structural brain correlates of theory of mind and empathy deficits in schizophrenia (2009) (153)
Daily sessions of transcranial magnetic stimulation to the left prefrontal cortex gradually reduce cocaine craving. (2008) (153)
Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. (1998) (152)
A length polymorphism in the circadian clock gene Per3 influences age at onset of bipolar disorder (2008) (150)
Opposite effects of suicidality and lithium on gray matter volumes in bipolar depression. (2011) (145)
Morning light treatment hastens the antidepressant effect of citalopram: a placebo-controlled trial. (2003) (145)
Augmentation effect of repetitive transcranial magnetic stimulation over the orbitofrontal cortex in drug-resistant obsessive-compulsive disorder patients: a controlled investigation. (2009) (142)
Dark therapy for mania: a pilot study. (2005) (141)
Sleep loss, a possible factor in augmenting manic episode (1996) (140)
Chronotherapeutics in a psychiatric ward. (2007) (138)
Lithium and GSK3-β Promoter Gene Variants Influence White Matter Microstructure in Bipolar Disorder (2013) (132)
Distribution of a novel mutation in the first exon of the human dopamine D4 receptor gene in psychotic patients (1993) (130)
Total sleep deprivation combined with lithium and light therapy in the treatment of bipolar depression: replication of main effects and interaction (2000) (130)
Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. (1998) (128)
Tract-specific white matter structural disruption in patients with bipolar disorder. (2011) (128)
Morbidity risk for obsessive-compulsive spectrum disorders in first-degree relatives of patients with eating disorders. (2001) (124)
Sustained Antidepressant Effect of Sleep Deprivation Combined with Pindolol in Bipolar Depression: A Placebo-Controlled Trial (1999) (116)
Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. (2000) (115)
Tryptophan hydroxylase gene associated with paroxetine antidepressant activity (2001) (113)
Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study. (1998) (113)
The Brief Assessment of Cognition in Schizophrenia. Normative data for the Italian population (2008) (112)
The unipolar–bipolar dichotomy and the response to sleep deprivation (1998) (110)
The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments (2005) (109)
Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. (1996) (109)
Deranged anterior pituitary responsiveness to hypothalamic hormones in depressed patients. (1978) (108)
Serotonin transporter gene associated with lithium prophylaxis in mood disorders (2001) (107)
Early onset of lithium prophylaxis as a predictor of good long-term outcome (1999) (106)
Serotonin transporter gene (5-HTTLPR) is not associated with depressive symptomatology in mood disorders (1999) (101)
Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. (2002) (100)
A genetic study of affective disorders (1977) (99)
Transcranial magnetic stimulation in treatment-resistant depressed patients: A double-blind, placebo-controlled trial (2005) (98)
Does rTMS hasten the response to escitalopram, sertraline, or venlafaxine in patients with major depressive disorder? A double-blind, randomized, sham-controlled trial. (2005) (98)
Dysfunctional brain circuitry in obsessive–compulsive disorder: Source and coherence analysis of EEG rhythms (2010) (98)
Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study. (1998) (97)
5-HT2A receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study (2003) (95)
Computer-aided neurocognitive remediation as an enhancing strategy for schizophrenia rehabilitation (2009) (95)
Complex segregation analysis for obsessive compulsive disorder and related disorders. (1999) (95)
Influence of catechol-O-methyltransferase Val158Met polymorphism on neuropsychological and functional outcomes of classical rehabilitation and cognitive remediation in schizophrenia (2007) (95)
Phase Advance Is an Actimetric Correlate of Antidepressant Response to Sleep Deprivation and Light Therapy in Bipolar Depression (2007) (94)
Serotonin transporter gene (5-HTTLPR) and major psychoses (2002) (94)
A family study of schizotypal disorder. (1995) (92)
Ongoing lithium treatment prevents relapse after total sleep deprivation. (1999) (92)
Antidepressant effects of light therapy combined with sleep deprivation are influenced by a functional polymorphism within the promoter of the serotonin transporter gene (2003) (92)
Fluvoxamine alone in the treatment of delusional depression. (1996) (91)
Neural and genetic correlates of antidepressant response to sleep deprivation: a functional magnetic resonance imaging study of moral valence decision in bipolar depression. (2007) (87)
Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders. (1999) (84)
Fronto-limbic disconnection in bipolar disorder (2015) (83)
Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial (2011) (82)
SSRIs antidepressant activity is influenced by Gβ3 variants (2003) (82)
A double-blind, randomised, controlled clinical trial of acetyl-l-carnitine vs. amisulpride in the treatment of dysthymia (2006) (81)
The development of the Metacognition Assessment Interview: Instrument description, factor structure and reliability in a non-clinical sample (2012) (79)
Neuroendocrine abnormalities in depressive illness. (1982) (78)
Abnormal pattern of platelet APP isoforms in Alzheimer disease and Down syndrome. (1996) (77)
Amino acid patterns in schizophrenia: Some new findings (1990) (76)
The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting (2009) (75)
Increased 5-Hydroxytryptamine-2 Receptor Binding in the Frontal Cortex of Depressed Patients Responding to Paroxetine Treatment: A Positron Emission Tomography Scan Study (2001) (75)
Tryptophan hydroxylase polymorphism and suicidality in unipolar and bipolar affective disorders: a multicenter association study (2001) (73)
Analysis of the D4 dopamine receptor gene variant in an Italian schizophrenia kindred. (1994) (73)
Clock genes beyond the clock: CLOCK genotype biases neural correlates of moral valence decision in depressed patients (2007) (73)
Outcomes on lithium treatment as a tool for genetic studies in affective disorders. (1984) (72)
Behavioural sensitization to repeated sleep deprivation in a mice model of mania (2008) (72)
Interleukine-6 serum levels correlate with response to antidepressant sleep deprivation and sleep phase advance (2002) (71)
Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. (2004) (71)
Cognitive performances associate with measures of white matter integrity in bipolar disorder. (2015) (71)
The Leucocyte Antigenic System HL-A as a Possible Genetic Marker of Schizophrenia (1974) (71)
‘Theory’ of mind impairment in patients affected by schizophrenia and in their parents (2009) (70)
Theory of mind and emotion processing training for patients with schizophrenia: Preliminary findings (2012) (70)
Family-based association study of 5-HTTLPR, TPH, MAO-A, and DRD4 polymorphisms in mood disorders. (2002) (69)
Response to clozapine in acute mania is more rapid than that of chlorpromazine (1997) (69)
DRD4 exon 3 variants associated with delusional symptomatology in major psychoses: a study on 2,011 affected subjects. (2001) (67)
Widespread changes of white matter microstructure in obsessive–compulsive disorder: Effect of drug status (2013) (67)
A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. (2001) (67)
Abnormalities of cAMP signaling in affective disorders: implication for pathophysiology and treatment. (2000) (65)
Abnormalities of cyclic adenosine monophosphate signaling in platelets from untreated patients with bipolar disorder. (1999) (65)
How do genes exert their role? Period 3 gene variants and possible influences on mood disorder phenotypes (2007) (64)
Response to SSRIs and role of the hormonal therapy in post-menopausal depression (2007) (64)
HL-A antigens and multiple sclerosis. (1972) (64)
Identification of symptomatologic patterns common to major psychoses: proposal for a phenotype definition. (1996) (64)
Tolerance and withdrawal with zolpidem (1993) (63)
Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine (2010) (63)
Family study of schizophrenia: exploratory analysis for relevant factors. (1986) (63)
Pharmacogenetics in affective disorders. (2002) (62)
Dopamine receptor D2 Ser/Cys 311 variant is associated with delusion and disorganization symptomatology in major psychoses (2000) (62)
Association study of MAO-A, COMT, 5-HT2A, DRD2, and DRD4 polymorphisms with illness time course in mood disorders. (2002) (62)
Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders. (2000) (61)
Presynaptic Ca2+/calmodulin-dependent protein kinase II: autophosphorylation and activity increase in the hippocampus after long-term blockade of serotonin reuptake. (1995) (60)
Symptomatologic analysis of psychotic and non-psychotic depression. (1999) (60)
Excess of allele1 for α3 subunit GABA receptor gene (GABRA3) in bipolar patients: a multicentric association study (2002) (59)
Dopamine receptor D2 and D4 genes, GABAA alpha-1 subunit gene and response to lithium prophylaxis in mood disorders (1999) (59)
d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study (2005) (59)
Acute antidepressant response to sleep deprivation combined with light therapy is influenced by the catechol-O-methyltransferase Val(108/158)Met polymorphism. (2010) (59)
Tyrosine hydroxylase gene associated with depressive symptomatology in mood disorder. (1998) (59)
A Symptom-Specific Analysis of the Effect of High-Frequency Left or Low-Frequency Right Transcranial Magnetic Stimulation over the Dorsolateral Prefrontal Cortex in Major Depression (2010) (58)
Positive association of dopamine D2 receptor polymorphism with bipolar affective disorder in a European Multicenter Association Study of affective disorders. (2002) (58)
Olanzapine-induced neutropenia after clozapine-induced neutropenia (1999) (58)
Systematic screening for mutations in the coding region of the human serotonin transporter (5-HTT) gene using PCR and DGGE. (1996) (58)
Temporal lobe grey matter volume in schizophrenia is associated with a genetic polymorphism influencing glycogen synthase kinase 3‐β activity (2010) (57)
Circadian clock gene Per3 variants influence the postpartum onset of bipolar disorder (2011) (57)
Dose-response efficacy of paroxetine in preventing depressive recurrences: a randomized, double-blind study. (1998) (57)
Tryptophan hydroxylase gene and major psychoses (2001) (57)
Emotional reactivity in chronic schizophrenia: structural and functional brain correlates and the influence of adverse childhood experiences (2010) (57)
5‐HT1A polymorphism and self‐transcendence in mood disorders (2005) (57)
Depressive syndrome in major psychoses: a study on 1351 subjects (2004) (57)
Cognitive dysfunction and glutamate reuptake: Effect of EAAT2 polymorphism in schizophrenia (2012) (57)
Neural network analysis in pharmacogenetics of mood disorders (2004) (56)
Brightening Depression (2004) (56)
Clinical and demographic features of mood disorder subtypes (2002) (55)
Major psychoses symptomatology: factor analysis of 2241 psychotic subjects (2001) (55)
Exploring functioning in schizophrenia: Predictors of functional capacity and real-world behaviour (2017) (55)
Serotonin transporter promoter genotype and illness recurrence in mood disorders (2002) (55)
Effects of CLOCK gene variants and early stress on hopelessness and suicide in bipolar depression (2015) (55)
Mode of inheritance in mood disorder families according to fluvoxamine response (1998) (55)
Delineating psychopathologic clusters within dysthymia: a study of 512 out-patients without major depression. (1999) (54)
Role of serotonergic gene polymorphisms on response to transcranial magnetic stimulation in depression (2007) (54)
Intracellular Lithium Concentration and Clinical Response (1975) (54)
Abnormalities of cAMP-dependent endogenous phosphorylation in platelets from patients with bipolar disorder. (1995) (54)
Factors affecting cognitive remediation response in schizophrenia: The role of COMT gene and antipsychotic treatment (2014) (54)
Adverse childhood experiences influence white matter microstructure in patients with bipolar disorder (2014) (54)
Clozapine-induced hypersensitivity myocarditis. (2004) (54)
Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment. (2004) (54)
White matter microstructure in bipolar disorder is influenced by the serotonin transporter gene polymorphism 5‐HTTLPR (2015) (53)
Neuroimaging and genetics of antidepressant response to sleep deprivation: implications for drug development. (2009) (53)
An association study between schizophrenia and the dopamine receptor genes DRD3 and DRD4 using haplotype relative risk. (1994) (52)
A double-blind study of long-term treatment with sertraline or fluvoxamine for prevention of highly recurrent unipolar depression. (1997) (52)
SSRIs antidepressant activity is influenced by G beta 3 variants. (2003) (52)
Serotonin transporter gene influences the time course of improvement of “core” depressive and somatic anxiety symptoms during treatment with SSRIs for recurrent mood disorders (2007) (51)
Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders (2004) (51)
Addiction and empathy: a preliminary analysis (2013) (51)
Serotonin transporter gene-linked polymorphic region: possible pharmacogenetic implications of rare variants (2006) (50)
An explorative study on metacognition in obsessive-compulsive disorder and panic disorder. (2012) (50)
Social adjustment and self-esteem in remitted patients with mood disorders (1999) (50)
Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study. (1997) (49)
Spectroscopic correlates of antidepressant response to sleep deprivation and light therapy: A 3.0 Tesla study of bipolar depression (2009) (49)
Dopamine agonist amineptine prevents the antidepressant effect of sleep deprivation (1996) (48)
Protein kinase A and Rap1 levels in platelets of untreated patients with major depression (2001) (48)
No association between dopamine D2 and D4 receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors (2001) (47)
Association between GSK-3β -50T/C polymorphism and personality and psychotic symptoms in mood disorders (2008) (47)
Factor analysis of delusional disorder symptomatology. (1999) (47)
Theory of Mind intervention for outpatients with schizophrenia (2013) (47)
Association between catechol-O-methyltransferase Val(108/158)Met polymorphism and psychotic features of bipolar disorder. (2010) (47)
Tryptophan depletion in obsessive-compulsive patients (1996) (46)
Plasma tryptophan to large neutral amino acids ratio and therapeutic response to a selective serotonin uptake inhibitor. (1994) (46)
Influence of 5-HTTLPR and TPH variants on illness time course in mood disorders. (2001) (46)
Shared reduction of oscillatory natural frequencies in bipolar disorder, major depressive disorder and schizophrenia. (2015) (46)
Gene-gene interaction of glycogen synthase kinase 3-β and serotonin transporter on human antidepressant response to sleep deprivation. (2012) (46)
Sleep deprivation hastens the antidepressant action of fluoxetine (2008) (45)
Changes of cortical excitability as markers of antidepressant response in bipolar depression: preliminary data obtained by combining transcranial magnetic stimulation (TMS) and electroencephalography (EEG) (2014) (45)
Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial (2010) (44)
Psychopathological and neuropsychological correlates of source monitoring impairment in schizophrenia (2007) (44)
Dopamine receptor D3 gene and response to lithium prophylaxis in mood disorders. (1998) (44)
Role of COMT, 5‐HT1A, and SERT genetic polymorphisms on antidepressant response to transcranial magnetic stimulation (2011) (44)
Sertraline Versus Fluvoxamine in the Treatment of Elderly Patients With Major Depression: A Double-blind, Randomized Trial (2005) (43)
Pharmacogenetics of lithium prophylaxis in mood disorders: analysis of COMT, MAO-A, and Gbeta3 variants. (2002) (43)
Improvement of cognitive functioning in mood disorder patients with depressive symptomatic recovery during treatment: An exploratory analysis (2006) (43)
Effects of Fluvoxamine Treatment on the in Vivo Binding of [F-18]FESP in Drug Naive Depressed Patients: A Pet Study (2000) (42)
Abnormal cortico-limbic connectivity during emotional processing correlates with symptom severity in schizophrenia (2015) (42)
Computer-aided neurocognitive remediation in schizophrenia: Durability of rehabilitation outcomes in a follow-up study (2010) (41)
A study of relapses in subjects with mood disorder on lithium treatment (1993) (41)
Interference between anti-HLA antibodies and chlorpromazine (1976) (41)
HLA system and affective disorders: a sibship genetic study. (1978) (41)
Dopamine receptor D2 Ser/Cys311 variant associated with disorganized symptomatology of schizophrenia (1998) (41)
Genetic variants of dopamine receptor D4 and psychopathology. (1998) (39)
Modulation by muscarinic antagonists of the response to carbon dioxide challenge in panic disorder. (2001) (39)
Tardive Dyskinesia Outcomes: Clinical and Pharmacologic Correlates of Remission and Persistence (1993) (39)
Combined social cognitive and neurocognitive rehabilitation strategies in schizophrenia: neuropsychological and psychopathological influences on Theory of Mind improvement (2015) (39)
A comparison between delusional and non-delusional depressives. (1992) (38)
The serotonin transporter genotype modulates the relationship between early stress and adult suicidality in bipolar disorder (2014) (38)
No association between schizophrenia and the serotonin receptor 5HTR2a in an Italian population. (1997) (38)
Changes in medial prefrontal cortex neural responses parallel successful antidepressant combination of venlafaxine and light therapy. (2009) (38)
Plasma tryptophan levels and plasma tryptophan/ neutral amino acids ratio in patients with mood disorder, patients with obsessive-compulsive disorder, and normal subjects (1992) (38)
Pooling pharmacogenetic studies on the serotonin transporter: A mega-analysis (2006) (38)
Catechol-O-methyltransferase gene variants in mood disorders in the Italian population. (2006) (37)
Factor analysis of mania. (1999) (37)
The Hla System and the Clinical Response to Treatment with Chlorpromazine (1976) (37)
Clinical and demographic features of psychotic and nonpsychotic depression. (1999) (37)
Long-term blockade of serotonin reuptake affects synaptotagmin phosphorylation in the hippocampus. (1997) (37)
Recurrence of bipolar mania is associated with catechol-O-methyltransferase Val(108/158)Met polymorphism. (2011) (36)
3-Methoxy-4-hydroxyphenylglycol and primary depression: clinical and pharmacological considerations. (1979) (36)
Lithium and GSK-3β promoter gene variants influence cortical gray matter volumes in bipolar disorder (2015) (36)
Detecting syntactic and semantic anomalies in schizophrenia (2015) (35)
Adverse childhood experiences influence the detrimental effect of bipolar disorder and schizophrenia on cortico-limbic grey matter volumes. (2016) (35)
Effects of Lithium on cAMP-Dependent Protein Kinase in Rat Brain (1998) (35)
Factors affecting the distribution of age at onset in patients with affective disorders. (1982) (35)
Serotonin 5-HT2A receptor gene variants influence antidepressant response to repeated total sleep deprivation in bipolar depression (2008) (35)
Two-year maintenance treatment with citalopram, 20 mg, in unipolar subjects with high recurrence rate. (1999) (35)
Lithium overcomes the influence of 5-HTTLPR gene polymorphism on antidepressant response to sleep deprivation. (2008) (35)
Multicentre Italian family‐based association study on tyrosine hydroxylase, catechol‐O‐methyl transferase and Wolfram syndrome 1 polymorphisms in mood disorders (2003) (35)
An assessment of the Wisconsin Card Sorting Test as an indicator of liability to schizophrenia (1994) (35)
Further studies on the major histocompatibility complex as a genetic marker for schizophrenia. (1976) (34)
cAMP-dependent phosphorylation system after short and long-term administration of moclobemide. (1998) (34)
Distribution of the MscI polymorphism of the dopamine D3 receptor in an Italian psychotic population. (1994) (34)
Delusional disorder and mood disorder: can they coexist? (1993) (34)
Analysis of depressive symptomatology in mood disorders (1998) (34)
No association of the Ser/Cys311 DRD2 molecular variant with schizophrenia using a classical case control study and the haplotype relative risk (1997) (33)
HTTLPR functional polymorphism in schizophrenia: Executive functions vs. sustained attention dissociation (2010) (33)
Disruption of white matter integrity marks poor antidepressant response in bipolar disorder. (2015) (33)
Serotonin transporter gene is not associated with symptomatology of schizophrenia (1999) (33)
Differential effects of lithium on platelet protein phosphorylation in bipolar patients and healthy subjects (1997) (33)
Impact of clinical variables on illness time course in mood disorders (2000) (33)
Cerebral D2 and 5-HT2 Receptor occupancy in Schizophrenic Patients Treated with Olanzapine Or Clozapine (2004) (33)
Dopamine receptor D4 gene is associated with delusional symptomatology in mood disorders (1998) (33)
Anxious depression : assessment and treatment (1987) (33)
Effect of glutamate transporter EAAT2 gene variants and gray matter deficits on working memory in schizophrenia (2014) (32)
Successful antidepressant chronotherapeutics enhance fronto-limbic neural responses and connectivity in bipolar depression (2015) (32)
The search for genetic homogeneity in affective disorders. (1984) (32)
Linkage of mood disorders with D2, D3 and TH genes: a multicenter study. (2000) (32)
Neural correlates of anxiety sensitivity in panic disorder: A functional magnetic resonance imaging study (2015) (32)
COMT Val158Met and 5-HT1A-R -1019 C/G polymorphisms: effects on the negative symptom response to clozapine. (2015) (31)
Clinical prediction of antidepressant response in mood disorders: Linear multivariate vs. neural network models (2007) (31)
Altered Rap1 endogenous phosphorylation and levels in platelets from patients with bipolar disorder. (2000) (31)
Assortative mating and affective disorders. (1979) (31)
A 24-month follow-up study of unipolar subjects: a comparison between lithium and fluvoxamine. (1994) (31)
A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA) (2007) (30)
Possible linkage between primary affective disorder susceptibility locus and HLA haplotypes. (1981) (30)
Dopamine receptor D4 gene is not associated with major psychoses. (1999) (30)
Fluvoxamine treatment of major depression associated with multiple sclerosis. (2004) (29)
Adverse childhood experiences influence white matter microstructure in patients with schizophrenia (2015) (29)
Familial patterns and possible modes of inheritance of primary affective disorders. (1981) (29)
Self-awareness of cognitive functioning in schizophrenia: Patients and their relatives (2012) (28)
Effects of fluvoxamine on the protein phosphorylation system associated with rat neuronal microtubules (1995) (28)
HLA-SD antigens and schizophrenia: statistical and genetical considerations. (2008) (28)
Pharmacogenetics of selective serotonin reuptake inhibitor response: a 6-month follow-up. (2004) (28)
Effect of 5-HT1A-receptor functional polymorphism on Theory of Mind performances in schizophrenia (2011) (28)
Patterns of symptom improvement during antidepressant treatment of delusional depression (2000) (27)
Caudate Gray Matter Volume in Obsessive-Compulsive Disorder Is Influenced by Adverse Childhood Experiences and Ongoing Drug Treatment (2012) (27)
Double-blind, randomized study of venlafaxine, clomipramine and trazodone in geriatric patients with major depression (1998) (27)
5HT‐2 receptor and fluvoxamine effect in obsessive‐compulsive disorder (1992) (27)
Neural correlates of delusion in bipolar depression (2014) (26)
Inhibitory effect of lithium on cAMP dependent phosphorylation system. (1996) (26)
Combined measure of smooth pursuit eye movements and ventricle-brain ratio in schizophrenic disorders (1987) (26)
Four-year follow-up study of sertraline and fluvoxamine in long-term treatment of unipolar subjects with high recurrence rate. (2000) (26)
Patterns of evidence integration in schizophrenia and delusion (2012) (26)
Cognitive Remediation and Functional Improvement in Schizophrenia: is it a Matter of Size? (2017) (26)
Seasonality and Sleep: A Clinical Study on Euthymic Mood Disorder Patients (2011) (25)
Dopamine receptor D4 is not associated with antidepressant activity of sleep deprivation (1999) (25)
cAMP signaling pathway in depressed patients with psychotic features (2002) (25)
Analytic considerations about observed distribution of age of onset in schizophrenia (1982) (24)
Exploring effects of EAAT polymorphisms on cognitive functions in schizophrenia. (2014) (24)
Rapid cycling mood disorder: clinical and demographic features. (2002) (24)
Immunogenetics of the Lennox‐Gastaut Syndrome: Frequency of HL‐A Antigens and Haplotypes in Patients and First‐Degree Relatives (1975) (24)
Serotonin-2A receptor gene is not associated with symptomatology of schizophrenia. (2000) (24)
Neural responses to emotional stimuli in comorbid borderline personality disorder and bipolar depression (2012) (23)
Serotonin transporter gene not associated with psychotic symptomatology of mood disorders (1999) (23)
A pilot, open study on the treatment of refractory schizophrenia with risperidone and clozapine (1995) (23)
Protein kinase A activity in platelets from patients with bipolar disorder. (2003) (23)
Optimized light therapy for non-seasonal major depressive disorder: effects of timing and season. (2012) (22)
Serotonin-2C and serotonin-1A receptor genes are not associated with psychotic symptomatology of mood disorders. (2000) (22)
Tyrosine hydroxylase gene in linkage disequilibrium with mood disorders (1998) (22)
Genetic Implications in Assortative Mating of Affective Disorders (1981) (22)
HLA typing and affective disorders: a study in the Italian population. (1978) (22)
Dopamine receptor D2 and D3 gene variants are not associated with the antidepressant effect of total sleep deprivation in bipolar depression (2003) (22)
A neural network model for combining clinical predictors of antidepressant response in mood disorders. (2007) (22)
Association of the C(-1019)G 5-HT1A promoter polymorphism with exposure to stressors preceding hospitalization for bipolar depression. (2011) (22)
The effect of verbalization strategy on wisconsin card sorting test performance in schizophrenic patients receiving classical or atypical antipsychotics (2006) (21)
Dopamine receptor sensitivity in the hypothalamus of chronic schizophrenics after haloperidol therapy: Growth hormone and prolactin response to stimuli (1979) (21)
Relapse during a 6-month continuation treatment with fluvoxamine in an Italian population: The role of clinical, psychosocial and genetic variables (2006) (21)
A psychometric–genetic study of schizotypal disorder 1 Part of the data included in this article were presented at the “Annual Niels Strandbygaard Lecture” held by the first author in Copenhagen, Denmark, on 21 November 1997. 1 (1999) (21)
Premorbid Functioning and Treatment Response in Recent-Onset Schizophrenia: Prospective Study With Risperidone Long-Acting Injectable (2011) (21)
Effect of reboxetine augmentation in SSRI resistant patients (2000) (21)
Worsening of delusional depression after sleep deprivation: case reports. (1999) (20)
No interaction of GABA(A) alpha-1 subunit and dopamine receptor D4 exon 3 genes in symptomatology of major psychoses. (1999) (20)
Stem Cell Factor (SCF) is a putative biomarker of antidepressant response (2016) (20)
Perspectives in clinical psychopharmacology of amitriptyline and fluvoxamine. A double-blind study in depressed inpatients. (1992) (20)
Migraine headache and mood disorders: a descriptive study in an outpatient psychiatric population. (2004) (20)
Predictive value of tryptophan/large neutral amino acids ratio to antidepressant response. (1996) (20)
Catechol-O-methyltransferase (COMT) genotype biases neural correlates of empathy and perceived personal distress in schizophrenia. (2013) (20)
Will a second prophylactic treatment with a higher dosage of the same antidepressant either prevent or delay new depressive episodes? (2000) (19)
Interference between anti-HLA antibodies and adrenergic receptor-binding drugs. (2008) (19)
GABAA alpha-1 subunit gene not associated with depressive symptomatology in mood disorders. (1998) (19)
Effects of acute intravenous clomipramine on obsessive-compulsive symptoms and response to chronic treatment (1995) (19)
Infradian mood fluctuations during a Major Depressive episode. (1996) (19)
Genetic bases of comorbidity between mood disorders and migraine: possible role of serotonin transporter gene (2010) (19)
Combined Neurocognitive And Metacognitive Rehabilitation In Schizophrenia: Effects On Bias Against Disconfirmatory Evidence (2015) (18)
Effect of early stress on hippocampal gray matter is influenced by a functional polymorphism in EAAT2 in bipolar disorder (2014) (17)
Perceived mood and skin body temperature rhythm in depression (1998) (17)
Agomelatine in depression (2013) (17)
Fluvoxamine and lithium in long-term treatment of unipolar subjects with high recurrence rate. (1996) (17)
No association between dopamine D(2) and D(4) receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors. (2001) (17)
Abnormal brain oscillations persist after recovery from bipolar depression (2017) (17)
Dopamine D3 receptor gene not associated with symptomatology of major psychoses. (1999) (17)
Seasonal concordance of recurrence in mood disorder patients (1995) (17)
Serotonin transporter and saitohin genes in risk of Alzheimer’s disease and frontotemporal lobar dementia: preliminary findings (2010) (16)
MHPG, amitriptyline and affective disorders. A longitudinal study. (1976) (16)
COMT and 5-HT1A-receptor genotypes potentially affect executive functions improvement after cognitive remediation in schizophrenia (2014) (16)
Possible relationship between outcome in primary affective disorders treated with lithium and family history. (1982) (16)
Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE) (2009) (15)
Lormetazepam in depressive insomnia: new evidence of phase-response effects of benzodiazepines (2004) (15)
Two new rare variants in the circadian “clock” gene may influence sleep pattern (2005) (15)
Sterol Regulatory Element Binding Transcription Factor-1 Gene Variation and Medication Load Influence White Matter Structure in Schizophrenia (2015) (14)
Risperidone long-acting injectable in recent-onset schizophrenia examined with clinician and patient self-report measures. (2010) (14)
Are gender differences in antiobsessional response related to different clomipramine metabolism? (2002) (14)
Neutral amino acid availability in two major psychiatric disorders (1995) (14)
Age at onset of affective disorders in Italian and Swedish patients (1987) (14)
A neural network approach to the outcome definition on first treatment with sertraline in a psychiatric population (2001) (14)
Dopamine D2 receptor gene not associated with symptomatology of mood disorders. (1999) (14)
N1-methylnicotinamide excretion and affective disorders (1976) (13)
Seasonal variations of lithium plasma levels (2002) (13)
Right hemisphere neural activations in the recall of waking fantasies and of dreams (2015) (13)
No interaction between serotonin transporter gene and dopamine receptor D4 gene in symptomatology of major psychoses. (1999) (13)
Genetic dissection of drug effects in clinical practice: CLOCK gene and clozapine-induced diurnal sleepiness (2004) (13)
A genetic linkage study of schizophrenia to chromosome 5 markers in a Northern Italian population (1992) (13)
ADDing a piece to the puzzle of cognition in schizophrenia. (2016) (13)
Differential efficacy of risperidone versus haloperidol in psychopathological subtypes of subchronic schizophrenia (2001) (13)
Plasma and intracellular kinetics of lithium after oral administration of various lithium salts (1977) (13)
EXECUTIVE DYSFUNCTION IN SCHIZOPHRENIA: POSSIBLE ROLE OF SAITOHIN GENE (2010) (13)
No association between serotonin-2A receptor gene polymorphism and psychotic symptomatology of mood disorders (1999) (12)
The Reality Monitoring Deficit as a Common Neuropsychological Correlate of Schizophrenic and Affective Psychosis (2013) (12)
Fluvoxamine vs clomipramine treatment in obsessive-compulsive disorder: A preliminary study (1992) (12)
Use of polymerase chain reaction nad denaturing gradient gel electrophoresis to identify polymorphisms in three exons of dopamine D2 receptor gene in schizophrenic and delusional patients. (1992) (12)
Social adjustment could be associated with the serotonin transporter gene in remitted patients with mood disorders and healthy subjects (2005) (11)
Alexithymia and anxiety sensitivity in populations at high risk for panic disorder. (2012) (11)
Patterns of mood variation during antidepressant treatment. (1998) (11)
ERYTHROCYTE/PLASMA LITHIUM RATIOS (1977) (11)
Antipsychotic-Induced Tardive Dyskinesia (1995) (11)
Different Neural Responses to a Moral Valence Decision Task in Unipolar and Bipolar Depression (2013) (11)
Saitohin polymorphism and executive dysfunction in schizophrenia (2012) (11)
Sexually divergent effect of COMT Val/met genotype on subcortical volumes in schizophrenia (2018) (10)
The distribution of dimensional personality traits in an Italian general population (1991) (10)
COMT and STH polymorphisms interaction on cognition in schizophrenia (2015) (10)
P.1.119 Genetic dissection of psychopathological symptoms: Insomnia in mood disorders and CLOCK gene polymorphism (2003) (9)
The COMT Val158Met polymorphism moderates the association between cognitive functions and white matter microstructure in schizophrenia (2016) (9)
Genetic approach to the study of heterogeneity of affective disorders. (1987) (9)
Effects of neuroleptic treatments on peripheral opioid secretion. (1987) (9)
Paliperidone extended-release in patients with non-acute schizophrenia previously unsuccessfully treated with other oral antipsychotics (2014) (9)
Susceptibility to bipolar affective disorders and unipolar depression is influenced by allelic variation of functional serotonin transporter expression (1996) (9)
Adverse childhood experiences and gender influence treatment seeking behaviors in obsessive-compulsive disorder. (2014) (9)
Red blood cell plasma Li ratio variability in affective patients. (1987) (8)
Complex segregation analysis of obsessive compulsive and spectrum related disorders: 22.3 (1995) (8)
Supporting tools in psychiatric treatment decision-making: Sertraline outcome investigation with artificial neural network method (2005) (8)
Amisulpride versus fluoxetine in dysthymia: preliminary results of a double-blind comparative study (1996) (8)
Further evidence supporting the association between the dopamine receptor D2 Ser/Cys311 variant and disorganized symptomatology of schizophrenia. (2000) (8)
White matter alterations associate with onset symptom dimension in obsessive–compulsive disorder (2018) (8)
Increased concentrations of various amino acids in schizophrenic patients (1987) (8)
Psychoeducational group intervention in addition to antidepressant therapy as relapse preventive strategy in unipolar patients (2006) (8)
Light therapy and fluvoxamine in the treatment of bipolar psychotic depression: A pilot study (2009) (8)
HLA system, psychiatry and psychopharmacology. (1979) (8)
HLA typing on Italian multiple sclerosis population. (1978) (7)
A single nucleotide polymorphism in SLC1A1 gene is associated with age of onset of obsessive-compulsive disorder (2014) (7)
Self-esteem in remitted patients with mood disorders is not associated with the dopamine receptor D4 and the serotonin transporter genes (1998) (7)
Visual and audio emotion processing training for outpatients with schizophrenia: an integrated multisensory approach (2018) (7)
Serum cholinesterase in obsessive-compulsive disorder (1995) (7)
5HT-3 receptor and antiobsessional effect [1] (1992) (7)
Effect of HLA type on age at onset in schizophrenic disorders. (1985) (6)
Erratum: Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia (International Clinical Psychopharmacology (2000) 15, 1 (29-34)) (2000) (6)
Lack of association between tryptophan hydroxylase gene and psychotic symptomatology in schizophrenia (1999) (6)
New perspectives on techniques for the clinical psychiatrist: Brain stimulation, chronobiology and psychiatric brain imaging (2008) (6)
Searching Susceptibility Loci for Bipolar Disorder: A Sib Pair Study on Chromosome 12 (2009) (6)
Biochemical investigation of histidinemia in schizophrenic patients (1990) (6)
MHPG, Amitriptyline and Depression: A Collaborative Study (1977) (6)
Neurofunctional assessment of schizophrenia: A preliminary investigation of the presence of eye-tracking (SPEMS) and quality extinction test (QET) abno (1987) (6)
A genetic study of Tardive Dyskinesia in an Italian population of chronic schizophrenics (1996) (6)
Multiple sclerosis immunogenetics: a) associations between HL-A antigens and high measles antibody levels. b) existence of common MLR/immune response determinants in MS patients. (1974) (5)
Psychotropic drugs and their relationship with psychopathology of affective disorders. (1979) (5)
Length of anxiolytic treatment and benzodiazepine withdrawal symptoms: A double-blind study with clotiazepam (1990) (5)
clinical/metabolic correlation study after treatment (18F)FDG PET study in obsessive-compulsive disorder. A (2011) (4)
Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: A double-blind, randomised trial (2002) (4)
Genetic notes of schizophrenic disorders (1987) (4)
Genetic modelling in schizophrenia according to HLA typing (1986) (4)
P.1.112 Double-blind, randomized study of venlafaxine, clomipramine, and trazodone in geriatric patients with major depression (1997) (4)
Positive association of DRD4 exon 1 and 3 variants with major psychoses (1996) (4)
Amyloidosis in neonatally thymectomized and anti-lymphocyte serum treated mice. (1969) (4)
Increased lecithin-cholesterol acyltransferase activity in multiple sclerosis patients (1973) (4)
Selective serotonin reuptake inhibitors alone and in association with pindolol in the treatment of delusional depression (1998) (4)
Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-acting Injectable Versus Quetiapine: Randomized, Long-term, Open-label, Clinical Trial Results (constatre) (2009) (4)
[Immunogenetics of multiple sclerosis: relationship between histocompatibility antigens and susceptibility to the disease]. (1972) (3)
Use of electroconvulsive therapy in the city of Milan: a naturalistic study. (2010) (3)
N-methylnicotinamide excretion and affective disorders. (1976) (3)
The HLA System as a Possible Marker for Psychiatric Disorders (1979) (3)
Sustaining the effect of sleep deprivation. (1998) (3)
Cognitive Processes and Personality Disorders in Affective Patients (1989) (3)
Is urinary MHPG a real predictor of drug response in primary depression? (1982) (3)
Long-term treatment with citalopram in patients with highly recurrent forms of unipolar depression (2001) (3)
Analytic considerations about distribution of age of onset in schizophrenia. (1982) (3)
ENHANCEMENT OF NMDA‐MEDIATED TRANSMISSION IN SCHIZOPHRENIA: EFFECTS OF CYCLOSERINE (1992) (3)
P.3.14 Association study of COMT Val108/158Met polymorphism and treatment response to haloperidol, risperidone and clozapine (2009) (3)
PATIENT FUNCTIONING WITH FLEXIBLE DOSES OF PALIPERIDONE ER – A 6-MONTH PROSPECTIVE STUDY (2010) (3)
Endocrine function in multiple sclerosis possible correlation with immunitary phenomena. (1974) (3)
P.2.d.011 Fronto–limbic disconnection in bipolar disorder (2014) (3)
Segregation Analysis in Families of Affective Patients Subdivided According to Treatment Outcome and Personality Disorders (1989) (3)
Multiple sclerosis immunogenetics. A possible correlation with human leukocyte HL-A antigens. (1975) (3)
Dr. Zanardi and Colleagues Reply (1999) (2)
The HLA System and the Celinical Response to Treatment with Haloperidol (1979) (2)
Bromperidol decanoate vs placebo in treating schizophrenia in the residual phase (1990) (2)
P.3.06 A glycogen synthase kinase 3-ß -50 T/CSNP influences long-term response to lithium salts in bipolar illness (2005) (2)
An immunological approach to the treatment of epilepsy. (1976) (2)
Rare presentation of tardive dyskinesia. (1992) (2)
P.5.002 Fluvoxamine in the treatment of obsessive-compulsive disorder: A double-blind comparison with clomipramine (1996) (2)
Endocrine factors in depressive illness (1978) (2)
Effect of lithium treatment on the GH-clonidine test in affective disorders (2004) (2)
Immunogenetics of Lennox-Gastaut syndrome: search for LD determinants as genetic markers of the syndrome. (1978) (2)
9-OH risperidone response in risperidone poor responders: An open study of drug response concordance (2012) (2)
Reading newspapers as a tool in rehabilitation intervention. (1990) (2)
Quantitative analysis of the serum and C.S.F. immunoglobulin fractions in multiple sclerosis. (1973) (2)
Intragenic tetranucleotide repeat polymorphism at the human histidase (HAL) locus (1997) (2)
SELECTIVE SEROTONIN REUPTAKE INHIBITORS AND DELUSIONAL DEPRESSION. AUTHORS' REPLY (1999) (2)
Genetic influence on response to serotonergic antidepressants (2000) (2)
In vitro approaches to the pathogenetic mechanisms of multiple sclerosis by leukocyte migration inhibition. (1974) (2)
P03-126 - Patient Functioning with Flexible Doses of Paliperidone ER - a 6-month Prospective Study (2010) (2)
Vitamin E treatment of persistent tardive dyskinesia: a double-blind, placebo-controlled, cross-over study (1994) (1)
i S, Poletti S, Ermoli E, Bechi M, Cappa S, Venneri A, Smeraldi E,Cavallaro R. The Brief Assessment of Cognition in Schizophrenia. Normative datafor the Italian population (2008) (1)
EFFICACY AND TOLERABILITY AMONG PATIENTS WITH RECENT ONSET SCHIZOPHRENIA TREATED WITH RISPERIDONE LONG-ACTING INJECTABLE (RLAI) (2010) (1)
Prevalence and risk factors of involuntary movement disorders in a neuroleptic treated population: A comparison between schizophrenic spectrum and non-schizophrenic spectrum patients (1991) (1)
72-2 cAMP dependent phosphorylation system in the pharmacotherapy and pathophyslology of affective disorders (1997) (1)
A STANDARDIZED TREATMENT OF DELUSIONAL DEPRESSION; PRELIMINARY RESULTS (1992) (1)
cAMP signalling system in the pharmacotherapy and pathophysiology of bipolar disorder (2000) (1)
Comment on the potential role of ghrelin in the mechanism of sleep deprivation therapy for depression (2007) (1)
Histocompatibility antigens and effects of neuroactive drugs on phytohaemagglutinin stimulation of lymphocytes in vitro. (1977) (1)
Hippocampal serotonin-1 A receptor binding correlates with cortisol plasma levels in social anxiety disorder (2006) (1)
Cardiopulmonary complications of ergot-derivative dopamine agonists. Authors'reply (2004) (1)
Changes in brain glutamate correlate with antidepressant response to total sleep deprivation: a 3 T 1H-MRS study (2006) (1)
P-31 Four-year outcomes for maintenance therapies in unipolar subjects with high probability of recurrence (1996) (1)
Dysthymic disorder in an inpatient population. A descriptive study (1994) (1)
P.1.03 How do genes exert their role? Period 3 gene variants and possible influences on mood disorder phenotypes (2007) (1)
Metacognition Assessment Interview (2014) (1)
P-12-23 Fluvoxamine alone in the treatment of delusional depression (1996) (1)
Association study of schizophrenia and the histidase gene (1997) (1)
Nonpharmacological management of bipolar disorder (2013) (1)
[Bromperidol decanoate in the residual phase of schizophrenia]. (1996) (1)
Response to lithium therapy and the TH gene (1994) (1)
Plasma renin activity in primary and secondary depression (1977) (1)
89-4 Circadian mood fluctuation as a predictor of the antidepressant response to total sleep deprivation (1997) (1)
Growth Hormone Response to Clonidine Stimulation in Affective Disorders: Effects of Lithium Therapy (1989) (1)
P-12-25 Fluvoxamine and lithium in long-term treatment of unipolar subjects (1996) (1)
P.1.115 CLOCK gene and circadian mood fluctuations in bipolar depression (2003) (0)
Subject Index Vol. 26, 1992 (1992) (0)
Letter to the editor (1978) (0)
15 Hz Repetitive Transcranial Magnetic Stimulation Over the Left Prefrontal Cor- tex Reduces Cocaine Craving (2014) (0)
EXPERIMENTAL ENCEPHALOMYELITIS (1950) (0)
[Immunological mechanisms in the central nervous system]. (1972) (0)
Association between schizophrenia and DRD3 in a large Italian population (1996) (0)
S.07.08 Disrupted effective connectivity of emotional circuitry in schizophrenia: a dynamic causal modeling study (2014) (0)
P.3.c.063 Effect of 5-HT1a and catechol-O-methyl-transferase gene polymorphisms on negative symptom response to clozapine (2009) (0)
P.1.g.010 Exploring effects of EAATs polymorphisms on cognitive functions in schizophrenia (2012) (0)
P.3.a.009 Effects of the interaction between adducins and EAAT2 polymorphisms on cognition in schizophrenia: preliminary findings (2012) (0)
High-Dose Ziprasidone Monotherapy in Bipolar I Disorder Patients With Depressed or Mixed Episodes (2008) (0)
P.6.038 Supporting tools in psychopharmacology: Theartificial neural network method in psychiatric treatment decision making (2004) (0)
A familial validation of dissection between panic and generalized anxiety disorders (1990) (0)
P.1.046 Transcranial magnetic stimulation in combination with antidepressant drugs in major depression: Preliminary results (2005) (0)
Tardive dyskinesia outcomes: A study of possible clinical, pharmacological and signs body distribution prediction factors (1993) (0)
S23. Symposium: Progress in the Genetics of Psychiatric Disorders (2004) (0)
P.3.12 Association study of GSK-3β −50T/C polymorphism with executive performances in schizophrenia (2007) (0)
Fluvoxamine in combination with pindolol hastens the response of delusional depressives (1999) (0)
Familial concordance of SSRIs response as a tool for differentiating mood disorder pedigrees (2000) (0)
Association between schizophrenia and the dopamine receptor DRD4 (1994) (0)
5-HT2 receptors in depressed patients studied by [F-18]FESP and PET: Effects of depressive symptoms (2000) (0)
39-111 Differential effect of total sleep deprivation in unipolar and bipolar depression (1997) (0)
S.09.02 Predicting cognitive remediation outcome with genes (2012) (0)
14-56: Clozapine treatment of borderline personality disorder (1997) (0)
P.4.b.009 The white ‘matter’ in obsessive compulsive disorder: effect of pharmacological treatment and symptom dimensions models (2015) (0)
P.3.b.029 Antipsychotics, metabolic syndrome and schizophrenia: investigating the role of SREBF polymorphisms (2013) (0)
Variability of Cognitive Patterns in Subjects with Mood Disorder (1993) (0)
Dr. Benedetti and Colleagues Reply (2000) (0)
P.3.a.016 Effects of catechol-O-methyltransferase Val108/158Met and Saitohin q7r polymorphisms on cognitive functions in schizophrenia (2011) (0)
EPS volume 12 issue 2 Cover and Back matter (2003) (0)
P.6.a.012 Effects of transcranial neuromagnetic and neuroelectical stimulation on alcohol craving (2011) (0)
Prolactin concentrations after single and repeated oral doses of savoxepine in patients with chronic schizophrenia (1991) (0)
Interference of sulpiride with the mitogenic activation of lymphocytes cultured in vitro. (1976) (0)
Estimate of linkage between schizophrenia and TH using a logistic regressive model (1993) (0)
P.2.a.031 Serotonin transporter promoter genetic characterization: possible pharmacogenetic implications of rare alleles (2006) (0)
P.3.b.021 Interleukin-1β, cognition and metabolic syndrome in schizophrenia (2015) (0)
Contents, Vol. 44, 1994 (1994) (0)
Selective serotonin reuptake inhibitors and delusional depression [16] (multiple letters) (1999) (0)
Publisher’s Editorial (1985) (0)
Editorial: Biological Psychology/Pharmacopsychology (1985) (0)
39-112 Patterns of infradian mood variation in major depression (1997) (0)
P.1.i.030 The modulatory role of catechol-O-methyltransferase Val158Met polymorphism on the association between white matter microstructure and cognitive performances in schizophrenia (2015) (0)
P.4.013 Fronto-limbic disconnection in bipolar disorder (2014) (0)
[The illness is in the mind, not in the soul]. (2009) (0)
["Who are you?" Replying we design our future]. (2010) (0)
chlorpromazine.HLA system and the clinical response to treatment with (2012) (0)
S.27.04 Gene-environment interactions in complex psychiatric disorders (1996) (0)
P.1.123 CLOCK gene influences insomnia during antidepressant treatment (2003) (0)
Predictors for treatment response in recently diagnosed non-acute patients with schizophrenia (2011) (0)
P.1.b.027 Shared reduction of oscillatory natural frequencies in bipolar disorder, major depressive disorder and schizophrenia (2015) (0)
Reply to "Cardiopulmonary Complications of Ergot-Derivative Dopamine Agonists" (2004) (0)
Genetic control of the metabolism of neuroleptics: implications for the management of therapeutic dosages and side effects (1994) (0)
Receptor pathophysiology in chronic schizophrenia (1981) (0)
[Immunopathology of multiple sclerosis: relationship between the development of the disease and serum and cerebrospinal fluid C1-3 levels]. (1973) (0)
S-49-1 Genetic mechanisms in response to haloperidol and risperidone treatments (1996) (0)
Role of protein phosphorylation in bipolar illness: 12.5 (1995) (0)
P.4.e.004 Effect of repetitive TMS of the left orbitofrontal cortex in drug-resistant obsessive-compulsive patients: a controlled investigation (2008) (0)
PLASMA RATIO TRYPTOPHAN/NEUTRAL ANINOACIDS IN ANTIDEPRESSANT TREATMENT (1992) (0)
Predicting value of tryptophan/large neutral amino acids ratio on selective serotonin reuptake inhibitors. (1996) (0)
P.2.e.013 Searching susceptibility loci for bipolar disorder: a sib pairs study on chromosome 12 (2008) (0)
P.4.006 Disrupted effective connectivity of emotional circuitry in schizophrenia: a dynamic causal modeling study (2014) (0)
Sertraline versus fluvoxamine in the treatment of elderly depressed patients: A double-blind randomized trial (2001) (0)
P.8.a.047 Searching susceptibility loci for maniacal and depressive polarities in bipolar disorders: a sib pairs study on chromosome 12 (2006) (0)
Sexually divergent effect of COMT Val/met genotype on subcortical volumes in schizophrenia (2017) (0)
P.2.a.025 Exploratory study of actigraphic and psychometric measures in depressed patients treated with agomelatine or sertraline (2007) (0)
P.3.15 Neural correlates of distorted moralthinking in bipolar depression: a 3.0 T BOLD fMRl event-related study (2005) (0)
PREMORBID FUNCTIONING AND TREATMENT RESPONSE AMONG PATIENTS WITH RECENT ONSET SCHIZOPHRENIA: PROSPECTIVE STUDY WITH RISPERIDONE LONG-ACTING INJECTABLE-PROPEL STUDY (2010) (0)
Schizophrenia Bulletin Index—1994-95 (1995) (0)
NEW DRUGS IN THE TREATMENT OF BORDERLINE PERSONALITY DISORDER (1999) (0)
Remission in schizophrenia: clinical and educational aspects. The Remission Project (2008) (0)
P.3.d.082 Enhancing cognitive remediation therapy with transcranial direct current stimulation: preliminary findings in schizophrenia (2015) (0)
Prevalence and severity of neuroleptic-induced extrapyramidal side effects in schizophrenia and delusional disorder. Relationships with diagnosis (1992) (0)
P.3.e.016 Self-awareness of cognitive functioning in schizophrenia: patients and their relatives (2011) (0)
P.4.f.004 Genetic and clinical contributions underlying symptom dimension stability in adult obsessive-compulsive disorder (2015) (0)
P.4.004 Early onset of lithium prophylaxis as possible good prognostic factor for staging bipolar disorder (2013) (0)
58-1 Major findings in molecular genetic studies of affective disorders (1997) (0)
Reply: Correction to "Long-Term Pharmacotherapy of Obsessive-Compulsive Disorder (1997) (0)
Negative symptoms in schizophrenia: An open study placebo-fluvoxamine treatment added to neuroleptics (1994) (0)
N1-Methylnicotinamide urinary output in multiple sclerosis affected patients. (1975) (0)
Genetic Aspects in the Course and Outcome of Affective Disorders (1988) (0)
P.3.13 Lithium therapy reverses the influence of 5-HTTLPR gene polymorphism on anti-depressant response to sleep deprivation (2007) (0)
P.2.a.013 Role of serotonergic gene polymorphisms on response to transcranial magnetic stimulation in depression (2007) (0)
Medium-term effectiveness of a new, prolonged-release, atypical antipsychotic: an objectives-based observational study (2009) (0)
Psychiatric Diseases and Depression (2006) (0)
P.3.10 Association study of GSK-3β −50T/C polymorphism with haloperidol resistance in schizophrenia (2007) (0)
P.1.121 Rapid assessment of cognitive distorsions in major depression (2003) (0)
Stem Cell Factor (SCF) is a putative biomarker of antidepressant response (2016) (0)
THE NEUROPSYCHOLOGY OF FRONTAL LOBES IN THE OBSESSIVE COMPULSIVE DISORDER. (1992) (0)
90-8 Effects of an antidepressant treatment on S-adenosylmethlonine plasma levels (1997) (0)
P.3.05 Clock genotype biases neural correlates of moral valence decision in patients affected by bipolar depression (2007) (0)
A linkage study in Italian schizophrenic families Testing the chromosome 5 hypothesis (1993) (0)
90-88 Protein phosphorylation in bipolar patients (1997) (0)
P.2.a.019 An actigraphic registration of depressed patients treated with chronotherapeutics (2006) (0)
HALOPERIDOL PLASMA LEVELS AFTER FLUVOXAMINE ADDITION (1992) (0)
Outcome to treatment with lithium in affective patients and family history (1984) (0)
Examination of potential role of dopaminergic D2, D3 and D4 receptors genes in affective disorders: a european multicentric collaborative study (2000) (0)
Letter to editor (0)
Symptomatologic susceptibility genes in major psychoses (2000) (0)
P.3.b.013 Disrupted effective connectivity of emotional circuitry in schizophrenia: a dynamic causal modeling study (2014) (0)
Affective disorders segregation structures according to clinical and pharmacological features (1990) (0)
Positive association between bipolar affective disorder and tyrosine hydroxylase gene: 22.2 (1995) (0)
Anti-anxiety effects of a new diazepine derivative, etizolam. A multicenter, randomized, double-blind study (1991) (0)
P.1.116 Phase-response effects of lormetazepam in depressive insomnia (2003) (0)
S.05.05 Chronobiological treatment of bipolar depression (2003) (0)
P.3.12 Recovery from bipolar depression aftertotal sleep deprivation: a 3.0 T BOLD fMRl event-related study of moral thinking (2005) (0)
P.3.016 Temporal lobe grey matter volume in schizophrenia is influenced by glycogen synthase kinase 3-beta activity (2010) (0)
P.2.a.012 Genetic bases of comorbidity between mood disorders and migraine: possible role of serotonin transporter gene (2007) (0)
Subject Index Vol. 4, 1978 (1978) (0)
A FAMILY STUDY OF OBSESSIVE‐COMPULSIVE PATIENTS (1992) (0)
P.1.e.021 Neural correlates of emotional self in bipolar disorder: a BOLD functional MRI 3 T study (2006) (0)
P.4.a.003 Aripiprazole augmentation of fluvoxamine in poor-insight obsessive-compulsive patients (2006) (0)
P.1.117 Morning light therapy as an augmenting strategy of antidepressant treatment (2003) (0)
Influence of brain activity at the baseline on antidepressant response to chronotherapeutic treatments: a fMRI study (2006) (0)
Correction to 'long-term pharmacotherapy of obsessive-compulsive disorder: A double-blind controlled study' (multiple letters) [10] (1997) (0)
P.1.e.020 Caudate grey matter volume in obsessivecompulsive disorder is influenced by adverse childhood experiences and ongoing drug treatment (2011) (0)
P.3.b.034 Interaction of EAAT2 genotype and clozapine on cognitive remediation outcome (2014) (0)
P.2.g.007 Influence of clock gene polymorphism on sleep-wake cycle in depressed bipolar patients: an actigraphic study (2006) (0)
[Etiopathogenetic implications of viral infections during a course of multiple sclerosis: study of cellular immunity against measles and parotitis virus]. (1973) (0)
Relevance of recent genetic studies for social psychiatry (1998) (0)
No influence of 5-HTTLPR and TPH polymorphisms on illness time course in mood disorders (2000) (0)
Editorial: Biological Psychiatry/Pharmacopsychiatry (1985) (0)
Influence of serotonin transporter promoter polymorphism on brain activation during a moral valence decision task (2006) (0)
P.1.120 Glycogen synthase kinase 3-b influences age at onset of bipolar disorder (2003) (0)
P.3.f.023 Effect of COMT functional polymorphism on bias against disconfirmatory evidence in schizophrenia (2013) (0)
99-1 SSRIs in the treatment of delusional depression (1997) (0)
P.1.118 Changes in depressive neuropsychological functioning during antidepressant treatment (2003) (0)
Symptomatologic structure extraction of major psychosis and association with DRD4 exon 1 and 3 variants: 14.2 (1995) (0)
Effect of fluvoxamine on cerebral serotoninergic receptors assessed by PET and [F-18]FESP in drug naive depressed patients (1998) (0)
Subject Index Vol. 44, 1994 (1994) (0)
P.2.e.008 Searching susceptibility loci for mania: a sib pairs pilot study (2007) (0)
Genetic predictors of treatment response in mood disorders (2000) (0)
Lithium Treatment: Relationship Between Relapses and Personality Disorders (1993) (0)
P.4.014 Clozapine treatment of severe tardive dystonia (1996) (0)
Interference between anti-HLA antibodies and CPZ metabolites (2004) (0)
[Genetic studies and their relevance in social psychiatry]. (1998) (0)
[Mechanisms of protection against the experimental allergic encephalomyelitis in the rabbit]. (1972) (0)
Psychiatric disorders in families of phenylketonuric patients (1990) (0)
90-129 Lithium and SSRIs in long-term treatment of unipolar subjects with high recurrence rate (1997) (0)
Dopaminergic and Serotoninergic Function in Drug-Free Schizophrenic Patients Assessed with PET and [18F]FESP (1998) (0)
P.1.11 Is the serotonin transporter gene a predictor for longevity? (2007) (0)
Genetic linkage and association studies of schizophrenia and related disorders using dopamine transporter gene markers (1994) (0)
Lithium and GSK-3β promoter gene variants influence cortical gray matter volumes in bipolar disorder (2014) (0)
P.3.c.033 Predictors for treatment response in non-acute patients with schizophrenia (2010) (0)
Long term outcome of drug-resistant bipolar depression: a 9 months prospective follow-up after chronotherapeutics (2006) (0)
S-33-5 Lithium effects on protein phosphorylation in bipolar and healthy subjects (1996) (0)
P.3.a.014 Exploring the effect of genetic variability of adducins on cognition in schizophrenia (2012) (0)
The safety of a rapid switch from tricyclic antidepressants to brofaromine (1991) (0)
A DESCRIPTIVE STUDY OF MANIC EPISODES IN A SAMPLE OF BIPOLAR SUBJECTS WITH DIFFERENT POLARITY OF ONSET (1992) (0)
SAVOXEPINE AND PROLACTIN CONCENTRATIONS AFTER SINGLE (LOADING)AND REPEATED DOSE ADMINISTRATION (1992) (0)
Noxiptylin and masked depression. (1978) (0)
Psychoendocrinological studies in chronic schizophrenia (1978) (0)
P.1.21 The COMT Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting (2009) (0)
GABRA1 as a possible candidate gene for bipolar disorder (1996) (0)
S-11-3 Protein phosphorylation system as a biochemical marker to study onset of antidepressant action (1995) (0)
Role of protein phosphorylation in bipolar disorder and in the action of lithium (1995) (0)
[Study of adrenal gland function in multiple sclerosis]. (1972) (0)
Self-esteem in remitted patients with mood disorders is not associated with the dopamine receptor D and the (1998) (0)
Reply to Comments by Dr Rico-villademoros (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Enrico Smeraldi?

Enrico Smeraldi is affiliated with the following schools:

Vita-Salute San Raffaele University

Enrico Smeraldi's Academic­Influence.com Rankings

Why Is Enrico Smeraldi Influential?

Enrico Smeraldi's Published Works

Published Works

What Schools Are Affiliated With Enrico Smeraldi?

Enrico Smeraldi's AcademicInfluence.com Rankings